NDA 208447/S-019
NDA 208447/S-020

SUPPLEMENT APPROVAL/
FULFILLMENT OF POSTMARKETING REQUIREMENT

GlaxoSmithKline LLC.
Attention: Alexander Polacheck, PhD
Associate Director, Regulatory Affairs
1000 Winder Street, North
Waltham, MA 02451

Dear Dr. Polacheck:

Please refer to your supplemental new drug applications (sNDAs) dated and received September 3, 2020 (S-019) and September 29, 2020 (S-020), and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zejula (niraparib) Capsules, 100 mg.

These Prior Approval supplemental new drug applications provide for revisions to the United States Prescribing Information (USPI) to add the following:

Supplement 019

- Addition of Posterior Reversible Encephalopathy Syndrome to Section 5, Warnings and Precautions
- Addition of Allergic Reactions to FD&C Yellow No. 5 (Tartrazine) to Section 5, Warnings and Precautions
- Addition of hypertensive crisis to Subsection 6.2, Postmarketing Experience
- Addition of pancytopenia to Section 5, Warnings and Precautions and Subsection 6.2, Postmarketing Experience
- Heading for Subsection 5.3 was modified to include ‘Hypertension’
- Updates were made to the Highlights of Prescribing Information, Section 17 Patient Couseling Information and the Patient Information sections of the label to reflect the above mentioned revisions.

Supplement 020

- Addition of a new Subsection 2.4 Dosage Adjustment for Hepatic Impairment, to Section 2, Dosage and Administration

- Updates to Subsection 8.7 Hepatic Impairment and Subsection 12.3 Pharmacokinetics, following the completion of Study 3000-01-003

APPROVAL & LABELING

We have completed our review of these applications, as amended. The applications are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the Food and Drug Administration (FDA) automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these new drug applications (NDAs), including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING REQUIREMENT

We have received your submission dated September 29, 2020, containing the final report for the following postmarketing requirement listed in the March 27, 2017, approval letter:

3187-1	Conduct a dedicated pharmacokinetic trial in patients with moderate hepatic impairment to determine an appropriate starting dose of niraparib in patients with moderate hepatic impairment.

This completes all of your postmarketing requirements and postmarketing commitments acknowledged in our March 27, 2017, letter.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.*[3]

[3] For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.[4] Information and Instructions for completing the form can be found at FDA.gov.[5]

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kim J. Robertson, Senior Regulatory Health Project Manager, at (301) 796-1441.

Sincerely,

{See appended electronic signature page}

Shaily Arora, PharmD
Associate Director for Safety (Acting)
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert

[4] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
[5] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

---

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

SHAILY ARORA
03/03/2021 01:43:30 PM